Compare BOXL & NXTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BOXL | NXTS |
|---|---|---|
| Founded | 1985 | 2009 |
| Country | United States | Israel |
| Employees | N/A | 9 |
| Industry | Telecommunications Equipment | Agricultural Chemicals |
| Sector | Telecommunications | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3M | 3.7M |
| IPO Year | 2015 | N/A |
| Metric | BOXL | NXTS |
|---|---|---|
| Price | $0.77 | $5.42 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 68.1K | 32.0K |
| Earning Date | 04-16-2026 | 05-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $25,743,612.00 | N/A |
| Revenue This Year | $2.70 | N/A |
| Revenue Next Year | $5.00 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 26.37 | N/A |
| 52 Week Low | $0.50 | $0.55 |
| 52 Week High | $10.15 | $6.75 |
| Indicator | BOXL | NXTS |
|---|---|---|
| Relative Strength Index (RSI) | 38.51 | 50.87 |
| Support Level | $0.70 | $3.97 |
| Resistance Level | $0.95 | $5.31 |
| Average True Range (ATR) | 0.07 | 0.68 |
| MACD | -0.00 | -0.08 |
| Stochastic Oscillator | 23.53 | 22.45 |
Boxlight Corp is a technology company that develops, sells, and services interactive solutions predominantly for the education market but also for the corporate and government sectors. The company currently designs, produces, and distributes interactive technologies, including interactive and non-interactive flat panel displays, LED video walls, media players, classroom audio and campus communication, cameras, and other peripherals for the education market and non-interactive solutions, including flat-panels, LED video walls, and digital signage for the enterprise market. It has three reportable segments - Europe, Middle East and Africa (EMEA), and North and Central America (Americas). The majority of revenue is derived from the sale of education technology products in the EMEA segment.
Nexentis Technologies Inc, is engaged in redefining mitochondrial drug discovery with help of its wholly owned biotechnology subsidiary, MitoCareX Bio focused on drug discovery company dedicated to developing first-in-class therapeutics for inflammatory metabolic diseases and cancer by targeting specific metabolic pathways. The company is also focused on sustainable operations in various industries such as solar projects, and oncology biotechnology.